Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality.
about
Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosisImpact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern AfricaAmbulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, IndiaThe effect of tuberculosis on mortality in HIV positive people: a meta-analysis.Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection.Effect of pulmonary tuberculosis on mortality in patients receiving HAART.Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda.Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand.Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia.Assessing tuberculosis case fatality ratio: a meta-analysis.Treatment outcome and mortality at one and half year follow-up of HIV infected TB patients under TB control programme in a district of South IndiaDepressed phagocytosis and oxidative burst in polymorphonuclear leukocytes from individuals with pulmonary tuberculosis with or without human immunodeficiency virus type 1 infection.Dysregulated production of interleukin-8 in individuals infected with human immunodeficiency virus type 1 and Mycobacterium tuberculosis.Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death.Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatmentFactors impacting early mortality in tuberculosis/HIV patients: differences between subjects naïve to and previously started on HAART.Timing, rates, and causes of death in a large South African tuberculosis programme.Tuberculosis and HIV disease: two decades of a dual epidemic.Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.Lean tissue mass wasting is associated with increased risk of mortality among women with pulmonary tuberculosis in urban UgandaModeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis.A Prediction Rule to Stratify Mortality Risk of Patients with Pulmonary Tuberculosis.Community-based rapid oral human immunodeficiency virus testing for tuberculosis patients in Lima, PeruTreatment outcome, mortality and their predictors among HIV-associated tuberculosis patients.Tropical respiratory medicine. 2. Impact of human immunodeficiency virus on tuberculosis in developing countriesHIV co-infection with tuberculous and non-tuberculous mycobacteria in western Kenya: challenges in the diagnosis and management.Recent advances in tropical medicineEffect of free treatment and surveillance on HIV-infected persons who have tuberculosis, Taiwan, 1993-2006.Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy.MenA is a promising drug target for developing novel lead molecules to combat Mycobacterium tuberculosis.Clinical features of tuberculosis among adults in sub-Saharan Africa in the 21st century.A new, clinically-based algorithm for the diagnosis of HIV in African tuberculosis patients: cross-sectional analysis from Mzuzu, Malawi.Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.Reintroducing antituberculosis therapy after Stevens-Johnson syndrome in human immunodeficiency virus-infected patients with tuberculosis: role of desensitization.Predictors of tuberculosis treatment outcomes.HIV in Zambia: myth or monster?Inhibition of human immunodeficiency virus-1 (HIV-1) by beta-chemokine analogues in mononuclear cells from HIV-1-infected patients with active tuberculosis.Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients.Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis.
P2860
Q24796366-AEE01CBD-4598-4B12-8D72-4F1AF36C3BBAQ28469286-6C38341A-B2EE-483C-84A0-C49414FCB6B1Q28476241-891CF551-A57E-41FB-82D0-00B5DD742A13Q28478204-E5A6D741-9E60-41E2-8094-206E8ADA1433Q30994512-62C16563-B23F-488E-9CD2-4C1373782AE8Q33254111-93F6E6F5-9E16-4D0B-BC71-A46E8EE6DC8CQ33764880-4A1772A1-557E-4BE2-B011-8B58A69C550EQ33847562-3474E2BD-88D1-4863-972E-80C4E3EA8104Q33884068-B818E863-0CD9-4B8F-8CB4-B433CD7FC568Q33901443-FB4E04C3-238F-496A-92B9-7C6E7F7BE78EQ33954598-7067CA43-3ED2-439B-84AC-D2490A8B67D7Q33981349-9A543257-E76B-418B-858F-D2A8E2B1F95DQ33993110-EC5BB3AC-0E94-49B0-8F73-53A8D4E08FB1Q34000599-AC4A06C8-0AA5-499D-A11A-55E79362759BQ34144133-4C0FCA25-A70F-459B-B520-83E27AA8A9A8Q34356631-0A297D84-3CAD-4992-ABF1-59599035F549Q34438327-33622A61-DECA-4984-8D9B-7BFEFDE9624EQ34979324-F49B5FF7-8A38-4CF5-8A8D-0400F37F042CQ35598500-A359BB7F-577D-4779-868B-6C863211E4D6Q35891202-8D293E50-0F36-431F-890B-D16130E9E61BQ36040147-AC2226CF-C7A1-4917-A0D3-4EBA4C1F63A6Q36070976-ED415EE3-B618-43CD-9E2B-9C154EDA1DEAQ36135526-85C0E027-C6BE-43B8-BDDC-6F904EC0EFFCQ36213203-EB940062-16B4-4F78-B3F6-685854CED954Q36390760-DCDADF0B-36EE-4A32-8492-CE4DA8FA62C5Q36566506-0ADAAF79-D329-43BC-BED6-B89FBAFB4C05Q36569762-05BF41CE-9924-48CF-90C7-FDB7993F6033Q36886014-BFCFDC01-E034-4ABF-BC61-C82AC883C63BQ37133326-26A7FA72-BEC5-4ECD-97E4-B13FF2774A03Q37500009-06F4CA6B-B716-4CC2-900C-1CA3A22ACF0DQ37735417-89BF4390-00F7-4ADD-A83F-4FCB51DF9C6EQ39334682-CB02B65B-C5F7-448F-A956-004D98E177C3Q39603987-80CA8E9A-9D7B-47EA-ADA6-8FE33F0DFF5DQ40800121-C333AA2D-DD2E-4752-B574-B9EF6261EDF5Q43778478-36D96B52-4266-45A3-9397-6AE639E9EC12Q44213840-94BEDBB1-75DA-47CF-8118-8B227F861AFBQ44232993-23589085-6F0B-45AD-88FE-F7577E5CB2E0Q45423213-55861917-2413-4AB3-8556-857E0E71FCCDQ45751006-BAB76BE2-0C04-4826-80EE-FDEF3D43267EQ46859480-1DD5047B-EF62-41BB-BAED-C83C60BE1460
P2860
Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Cohort study of human immunode ...... of early (6-month) mortality.
@en
Cohort study of human immunode ...... of early (6-month) mortality.
@nl
type
label
Cohort study of human immunode ...... of early (6-month) mortality.
@en
Cohort study of human immunode ...... of early (6-month) mortality.
@nl
prefLabel
Cohort study of human immunode ...... of early (6-month) mortality.
@en
Cohort study of human immunode ...... of early (6-month) mortality.
@nl
P2093
P2860
P921
P356
P1476
Cohort study of human immunode ...... of early (6-month) mortality.
@en
P2093
Carpenter L
Odhiambo J
P2860
P304
P356
10.1164/AJRCCM/146.4.849
P577
1992-10-01T00:00:00Z